about
Cardiac MR imaging: current status and future direction.Essentials of forensic post-mortem MR imaging in adultsT₂ -weighted MRI of post-infarct myocardial edema in mice.T2-weighted imaging to assess post-infarct myocardium at risk.Diagnostic and prognostic value of cardiovascular magnetic resonance in non-ischaemic cardiomyopathies.Global myocardial oedema in advanced decompensated heart failure.T2-weighted cardiovascular magnetic resonance in acute cardiac diseaseNon-contrast T1-mapping detects acute myocardial edema with high diagnostic accuracy: a comparison to T2-weighted cardiovascular magnetic resonance.Direct T2 quantification of myocardial edema in acute ischemic injury.Dynamic changes of edema and late gadolinium enhancement after acute myocardial infarction and their relationship to functional recovery and salvage indexRelationship of T2-Weighted MRI Myocardial Hyperintensity and the Ischemic Area-At-RiskA randomized prospective mechanistic cardiac magnetic resonance study correlating catheter stability, late gadolinium enhancement and 3 year clinical outcomes in robotically assisted vs. standard catheter ablationTargeting of Extracellular RNA Reduces Edema Formation and Infarct Size and Improves Survival After Myocardial Infarction in Mice.New echocardiographic findings correlate with intramyocardial inflammation in endomyocardial biopsies of patients with acute myocarditis and inflammatory cardiomyopathy.At-risk but viable myocardium in a large animal model of non ST-segment elevation acute coronary syndrome: cardiovascular magnetic resonance with ex vivo validationWhat can cardiac magnetic resonance do for cardiologists in China?Myocardial T1 mapping: modalities and clinical applications.Advanced Cardiac MR Imaging for Myocardial Characterization and Quantification: T1 MappingRole of Cardiac Magnetic Resonance Imaging in Myocardial Infarction.Nonischemic myocardial changes detected by cardiac magnetic resonance in critical care patients with sepsis.Early Gadolinium Enhancement for Determination of Area at Risk: A Preclinical Validation Study.
P2860
Q26786658-DE1175FA-57B0-4607-9200-4E71E4BDFC4BQ27023416-045C426B-94D7-466E-9449-2D9D5D3C6F06Q30423185-5DBC9D83-3DB7-404A-BDD2-BD8B190705C5Q30425254-3C868401-0C32-4B72-91DE-2A64D9A33931Q30463822-7B1D1A48-111C-4AA2-84CF-B86428A374F1Q31112487-973D97C0-02F4-4A8C-83B9-2347E906F784Q33824106-3430F5D4-E230-4534-9152-0A366C6856D3Q34312835-10185739-839B-4CB0-ABDC-1A73D17A4E08Q34808565-19DA0793-B7D0-4F9F-B4A0-8C5485A4447CQ34992842-83BE41E6-350F-49B8-97C5-7A2F64779B91Q35854853-2F769308-892E-4C2A-A98B-E3AC075A4C16Q35950560-378D16DC-C1A7-4D81-B0E1-8D790E77EA25Q36411767-88016734-9E32-4886-A88B-871BDE1D176DQ36739675-05DF7323-9FC5-4DFE-B862-D33B55111281Q37366218-905C1237-B677-432D-94DA-D8F79E7DFED0Q37382693-8BD6C958-F336-4EF5-885C-5654970CD940Q37717684-BDD21A08-2598-402C-9430-D2E2DD1DEEEBQ38081414-C8388D1B-72F5-4EFC-BB7D-6BF5AAADB3A4Q38635266-CBEEF286-4FCE-44A1-9755-D913A2A755FCQ42909468-F77607CE-2840-4017-8DDA-E8DF50875FA4Q46209344-E7FF5B38-795B-4F8E-81FD-3B626FBB6C42
P2860
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Myocardial edema--a new clinical entity?
@ast
Myocardial edema--a new clinical entity?
@en
Myocardial edema--a new clinical entity?
@nl
type
label
Myocardial edema--a new clinical entity?
@ast
Myocardial edema--a new clinical entity?
@en
Myocardial edema--a new clinical entity?
@nl
prefLabel
Myocardial edema--a new clinical entity?
@ast
Myocardial edema--a new clinical entity?
@en
Myocardial edema--a new clinical entity?
@nl
P2860
P356
P1476
Myocardial edema--a new clinical entity?
@en
P2093
Matthias G Friedrich
P2860
P2888
P304
P356
10.1038/NRCARDIO.2010.28
P407
P577
2010-03-23T00:00:00Z
P6179
1045197245